Vimarsana
Biggest News Aggregation in the World

Page 39 - Accessed August News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Accessed August. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Accessed August Today - Breaking & Trending Today

Enhertu Approved for HER2-Low Metastatic Breast Cancer - Vimarsana News

Enhertu Approved for HER2-Low Metastatic Breast Cancer

The FDA has approved Enhertu (fam-trastuzumab-deruxtecan-nxki) for adults with unresectable or metastatic HER2-low breast cancer.

Source: empr.com
New Indication for Nubeqa: Metastatic Hormone-Sensitive Prostate Cancer - Vimarsana News

New Indication for Nubeqa: Metastatic Hormone-Sensitive Prostate Cancer

The FDA has approved Nubeqa (darolutamide) plus docetaxel for the treatment of metastatic hormone-sensitive prostate cancer.

Source: empr.com
Citrate-Free Formulation of Taltz Now Available - Vimarsana News

Citrate-Free Formulation of Taltz Now Available

A new citrate-free formulation of Taltz® (ixekizumab) has been made available by Eli Lilly.

Source: empr.com
Stock Market | FinancialContent Business Page - Vimarsana News

Stock Market | FinancialContent Business Page

FinancialContent fully hosted finance channel

U.S. FDA Approves Additional Indication of NUBEQA® (darolutamide) in Combination with Docetaxel for - Vimarsana News

U.S. FDA Approves Additional Indication of NUBEQA® (darolutamide) in Combination with Docetaxel for

NUBEQA now has indications in both metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC)1Today’s approval under the FDA’s Real-Time Oncology Review (RTOR) pilot program was based on the pivotal Phase III ARASENS trial, which showed a significant overall...